GL 48656

Drug Profile

GL 48656

Alternative Names: GL-48656

Latest Information Update: 04 Mar 2008

Price : $50

At a glance

  • Originator Genelabs Technologies
  • Class Antifungals; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Aspergillosis

Most Recent Events

  • 26 Sep 2003 Data presented at the 43rd Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC-2003) have been added to the Bacterial infections antimicrobial activity and pharmacodynamics section ,,
  • 16 Sep 2003 GL 48656 is available for licensing (http://genelabs.com)
  • 26 Mar 2003 Preclinical trials in Aspergillosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top